Clinical Observation Of Radioactive ¹²⁵I Particles Implantation In The Treatment Of Non-small Cell Lung Cancer（NSCLC）

Objective:To observe the efficacy and side effects of radioactive ¹²⁵I particles implantation in the treatment of NSCLC.Methods:The clinical data of 426 patients with NSCLC who were hospitalized in the respiratory department of the First Affiliated Hospital of Nanchang University from May 2010 to August 2018 were collected.According to the treatment ways,the patients were divided into four groups:Simple particles implantation group（group A）,Particles implantation combined with chemotherapy group（group B）,Simple chemotherapy group（group C）.To analyze the clinical effect and adverse reactions of each group after treatment.Results:After starting treatment,the effective rates of the first,third and sixth month in each group were 75.9%/72.4%/65.5%（group A）,83.2%/78.8%/76.1%（group B）,46.2%/36.4%/33.2%（group C）.The median progression free survival was 8.5 months（group A）,12.5 months（group B）,3.7 months（group C）,respectively,and the median survival time of each group was 13.7months（group A）,16.4 months（group B）,7.2 months（group C）.The incidence of adverse reactions in group A was lower than that in group B and C,and the difference was statistically significant（P<0.05）.And there was no statistically significant when comparing the difference between the group B and group C.Conclusion:In the treatment of non-small cell lung cancer,the short-term effect of radioactive ¹²⁵I particles implantation is significant,and the adverse reactions are mild.It can improve the clinical benefit rate when combined with chemotherapy.we also found it can improve the quality of life of patients and is worthy of clinical promotion.